Showing posts with label HER3. Show all posts
Showing posts with label HER3. Show all posts
Monday, June 13, 2011
HER3 - Turning off cancer's growth signals (pancreatic/ovarian)
Drugs that interfere with HER3’s better-known cousins, EGFR and HER2, have already proven effective in treating many types of cancer, and early-stage clinical trials are underway with antibodies directed against HER3. HER3 is of great interest to cancer biologists because it is commonly involved in two of the deadliest forms of the disease, ovarian and pancreatic cancer, says MIT Professor Linda Griffith, who led the research team with Harvard Stem Cell Institute and Brigham and Women’s cardiologist Richard Lee.
The study, published online May 26 in the Journal of Biological Chemistry....
add your opinions
clinical trials
,
EGFR
,
HER2
,
HER3
Wednesday, February 24, 2010
Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer - abstract
Conclusion: Pertuzumab may add activity to gemcitabine for the treatment of platinum-resistant ovarian cancer. Low HER3 mRNA expression may predict pertuzumab clinical benefit and be a valuable prognostic marker.
add your opinions
Gemcitabine
,
HER3
,
Pertuzamab
Subscribe to:
Posts
(
Atom
)